AVR-RD-02

BIOLOGICAL2 trials

Sponsors

AVROBIO, John Bernat

Conditions

Gaucher Disease

Phase 1

Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease

TerminatedNCT04145037

AVROBIOGaucher Disease

Start: 2019-05-30End: 2023-08-21Updated: 2024-01-18

Unknown Phase

Long Term Follow-Up for Safety of AVR-RD-02

Active, not recruitingNCT06488261

John BernatGaucher Disease

Start: 2024-02-21End: 2037-10-31Updated: 2025-07-22